| Date | Title | Description |
| 12.11.2025 | ExpreS2ion and Serum Institute of India Enter Definitive Licensing Agreement for Malaria Vaccines | ExpreS2ion and Serum Institute of India Enter Definitive Licensing Agreement for Malaria Vaccines
Wed, Nov 12, 2025 12:29 CET Report this content
Hørsholm, Denmark, 12 November 2025 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Bio... |
| 12.11.2025 | Correction: ExpreS2ion and Serum Institute of India Enter Definitive Licensing Agreement for Malaria Vaccines | Correction: ExpreS2ion and Serum Institute of India Enter Definitive Licensing Agreement for Malaria Vaccines
Wed, Nov 12, 2025 14:20 CET Report this content
This press release is a correction to the press release made earlier this afternoo... |
| 07.11.2025 | ExpreS2ion Hereby Changes Certified Advisor to Redeye | ExpreS2ion Hereby Changes Certified Advisor to Redeye
Fri, Nov 07, 2025 14:00 CET Report this content
Hørsholm, Denmark, 7 November 2025 – ExpreS2ion Biotech Holding AB (publ) (“ExpreS2ion” or the “Company”) today announces it has entered i... |
| 03.11.2025 | ExpreS2ion to Participate in Key Investor and Industry Events in November 2025 | ExpreS2ion to Participate in Key Investor and Industry Events in November 2025
Mon, Nov 03, 2025 14:00 CET Report this content
Hørsholm, Denmark, 3 November 2025 – ExpreS2ion Biotech Holding AB’s subsidiary ExpreS2ion Biotechnologies ApS (“... |
| 12.09.2025 | ExpreS2ion to Present in Upcoming Investor Events | ExpreS2ion to Present in Upcoming Investor Events
Fri, Sep 12, 2025 10:00 CET Report this content
Hørsholm, Denmark, 12 September 2025 – ExpreS2ion Biotech Holding AB’s subsidiary ExpreS2ion Biotechnologies ApS (“ExpreS2ion") is please... |
| 04.09.2025 | ExpreS2ion Reports First Immunogenicity Data from HER2 Breast Cancer Vaccine ES2B-C001 Phase I Trial | ExpreS2ion Reports First Immunogenicity Data from HER2 Breast Cancer Vaccine ES2B-C001 Phase I Trial
Thu, Sep 04, 2025 08:45 CET Report this content
Hørsholm, Denmark, 4 September 2025 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion ... |
| 02.09.2025 | ExpreS2ion Biotech Highlights CEO Presentations at Økonomisk Ugebrev and ProHearings Investor Events | ExpreS2ion Biotech Highlights CEO Presentations at Økonomisk Ugebrev and ProHearings Investor Events
Tue, Sep 02, 2025 11:00 CET Report this content
Hørsholm, Denmark, 2 September 2025 – ExpreS2ion Biotech Holding AB’s (“ExpreS2ion” or the ... |
| 27.08.2025 | ExpreS2ion Biotech Announces Analysguiden Publishes Updated Equity Research Report; Price Target Maintained at SEK 75 | ExpreS2ion Biotech Announces Analysguiden Publishes Updated Equity Research Report; Price Target Maintained at SEK 75
Wed, Aug 27, 2025 15:15 CET Report this content
Hørsholm, Denmark, 27 August 2025 – ExpreS2ion Biotech Holding AB’s affili... |
| 21.08.2025 | ExpreS2ion Biotech Announces Pareto Securities Analyst Note on Q2 2025 Results; Buy Rating Maintained with Price Target at SEK 303 | ExpreS2ion Biotech Announces Pareto Securities Analyst Note on Q2 2025 Results; Buy Rating Maintained with Price Target at SEK 303
Thu, Aug 21, 2025 14:00 CET Report this content
Hørsholm, Denmark, 21 August 2025 – ExpreS2ion Biotech Holdin... |
| 21.08.2025 | ExpreS2ion Announces Financial Results for the First Half and Second Quarter of 2025 | ExpreS2ion Announces Financial Results for the First Half and Second Quarter of 2025
Thu, Aug 21, 2025 08:30 CET Report this content
Hørsholm, Denmark, 21 August 2025 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces its half-y... |
| 15.08.2025 | ExpreS2ion to Present in Upcoming Investor Events | ExpreS2ion to Present in Upcoming Investor Events
Fri, Aug 15, 2025 11:00 CET Report this content
Hørsholm, Denmark, 15 August 2025 – ExpreS2ion Biotech Holding AB’s subsidiary ExpreS2ion Biotechnologies ApS (“ExpreS2ion") is pleased t... |
| 18.07.2025 | ExpreS2ion Highlights Strategic Relevance of GHIT-Funded Malaria Vaccine Development Through Ownership in AdaptVac | ExpreS2ion Highlights Strategic Relevance of GHIT-Funded Malaria Vaccine Development Through Ownership in AdaptVac
Fri, Jul 18, 2025 11:50 CET Report this content
Hørsholm, Denmark, 18 July 2025 - ExpreS2ion Biotech Holding AB (Nasdaq First... |
| 17.07.2025 | Total Investment of Approx. USD 7.3 Million in Malaria and TB R&D Projects With Partners Including European Vaccine Initiative, University of Copenhagen, and University of Tübingen | TOKYO, July 17, 2025 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximately JPY 1 billion (USD 7.3 million1) in four R&D projects for the development of vaccine, drug, and... |
| 07.07.2025 | ExpreS2ion enters strategic agreement with DTU for access to the Computerome supercomputer | ExpreS2ion enters strategic agreement with DTU for access to the Computerome supercomputer
Mon, Jul 07, 2025 10:10 CET Report this content
Hørsholm, Denmark, 7 July 2025 - ExpreS2ion Biotech Holding AB (Nasdaq First North Growth Market: EXP... |
| 24.06.2025 | A New Dawn in Cancer Treatment and Quantum Computing: Innovations Reshape the Future | In the realm of healthcare and technology, two groundbreaking developments are emerging, each with the potential to reshape their respective fields. ExpreS2ion Biotech is making strides in cancer treatment with its innovative immunotherapy,... |
| 23.06.2025 | ExpreS2ion announces dosing of first patient in Phase I clinical trial of ES2B-C001, its novel therapeutic breast cancer immunotherapy | ExpreS2ion announces dosing of first patient in Phase I clinical trial of ES2B-C001, its novel therapeutic breast cancer immunotherapy
Mon, Jun 23, 2025 14:03 CET Report this content
Hørsholm, Denmark, 23 June 2025 - Today ExpreS2ion Biotec... |
| 19.06.2025 | ExpreS2ion’s associated company AdaptVac to lead CEPI and EU funded USD 12.4 million consortium to develop novel filovirus vaccine | ExpreS2ion’s associated company AdaptVac to lead CEPI and EU funded USD 12.4 million consortium to develop novel filovirus vaccine
Thu, Jun 19, 2025 09:39 CET Report this content
Hørsholm, Denmark, 19 June 2025 - ExpreS2ion Biotech Holding ... |
| 23.05.2025 | ExpreS2ion Biotech Announces Analysguiden Publishes Equity Research Report | ExpreS2ion Biotech Announces Analysguiden Publishes Equity Research Report
Fri, May 23, 2025 13:29 CET Report this content
Hørsholm, Denmark, 23 May 2025 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2io... |
| 07.02.2025 | ExpreS2ion Biotech: Navigating Challenges and Seizing Opportunities in 2024 | ExpreS2ion Biotech Holding AB stands at a crossroads. The company recently unveiled its financial results for the fourth quarter and full year of 2024. Like a ship weathering a storm, ExpreS2ion has faced challenges but also found new winds... |
| 06.02.2025 | ExpreS2ion announces financial results for the fourth quarter of 2024 | ExpreS2ion announces financial results for the fourth quarter of 2024
Thu, Feb 06, 2025 08:30 CET Report this content
Hørsholm, Denmark, 6 February 2025 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces its fourth quarter and f... |
| 12.12.2024 | ExpreS2ion Biotech: A Promising Horizon in Cancer Treatment | ExpreS2ion Biotech Holding AB is making waves in the biotechnology sector. The company, based in Hørsholm, Denmark, is on a mission to revolutionize vaccine development. Recently, it announced significant financial movements and clinical ad... |
| 11.12.2024 | Analysguiden Publishes Research Report on ExpreS2ion Biotech with Price Target of SEK 91 | Analysguiden Publishes Research Report on ExpreS2ion Biotech with Price Target of SEK 91
Wed, Dec 11, 2024 10:00 CET Report this content
Hørsholm, Denmark, 11 December 2024 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnolog... |
| 11.12.2024 | Publication of clinical Phase IIb trial data for the adjuvanted RH5.1 blood-stage malaria vaccine | Publication of clinical Phase IIb trial data for the adjuvanted RH5.1 blood-stage malaria vaccine
Wed, Dec 11, 2024 12:10 CET Report this content
Hørsholm, Denmark, 11 December 2024 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Bio... |
| 03.07.2024 | ExpreS2ion announces U.S. patent issue notification for glyco-engineered immunization antigens | ExpreS2ion announces U.S. patent issue notification for glyco-engineered immunization antigens
Wed, Jul 03, 2024 12:30 CET Report this content
Hørsholm, Denmark, 3 July 2024 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnolo... |
| 21.06.2024 | Publication of clinical Phase Ib trial data for the adjuvanted RH5.1 blood-stage malaria vaccine | Publication of clinical Phase Ib trial data for the adjuvanted RH5.1 blood-stage malaria vaccine
Fri, Jun 21, 2024 11:30 CET Report this content
Hørsholm, Denmark, 21 June 2024 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechn... |
| 04.01.2022 | ExpreS2ion announces further positive preclinical proof-of-concept results for the HER2-cVLP breast cancer vaccine | ExpreS2ion announces further positive preclinical proof-of-concept results for the HER2-cVLP breast cancer vaccine Tue, Jan 04, 2022 08:30 CET
Hørsholm, Denmark, January 4, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotech... |
| 22.12.2021 | ExpreS2ion announces positive topline results for its HER2-cVLP breast cancer vaccine, demonstrating animal proof-of-concept | ExpreS2ion announces positive topline results for its HER2-cVLP breast cancer vaccine, demonstrating animal proof-of-concept Wed, Dec 22, 2021 08:30 CET
Hørsholm, Denmark, December 22, 2021 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS... |
| 05.12.2021 | Positive topline results reported for the Phase II COVID-19 clinical trial with the ABNCoV2 vaccine | Positive topline results reported for the Phase II COVID-19 clinical trial with the ABNCoV2 vaccine Sun, Dec 05, 2021 19:45 CET
Hørsholm, Denmark, December 5, 2021 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (... |
| 15.11.2021 | ExpreS2ion’s Interim Report for Q3 2021 will be published today | ExpreS2ion’s Interim Report for Q3 2021 will be published today Mon, Nov 15, 2021 11:30 CET
Hørsholm, Denmark, November 15, 2021 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby announces that the company’s Interim Report for Q3 2021 w... |
| 12.11.2021 | Further efficacy data from the COVID-19 clinical Phase I/II study with ABNCoV2 confirms strong positive results | Further efficacy data from the COVID-19 clinical Phase I/II study with ABNCoV2 confirms strong positive results Fri, Nov 12, 2021 08:10 CET
Hørsholm, Denmark, November 12, 2021 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechn... |
| 23.08.2021 | ExpreS2ion’s Board and Management committed to fully exercise their TO5 warrants | ExpreS2ion’s Board and Management committed to fully exercise their TO5 warrants Mon, Aug 23, 2021 10:00 CET
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA... |
| 23.08.2021 | The ABNCoV2 COVID-19 vaccine program receives up to DKK 800 million from the Danish Ministry of Health | The ABNCoV2 COVID-19 vaccine program receives up to DKK 800 million from the Danish Ministry of Health Mon, Aug 23, 2021 14:53 CET
Hørsholm, Denmark, August 23, 2021 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS... |
| 09.08.2021 | Positive safety and efficacy outcome of the COVID-19 clinical Phase I/II study for the ABNCoV2 vaccine | Positive safety and efficacy outcome of the COVID-19 clinical Phase I/II study for the ABNCoV2 vaccine Mon, Aug 09, 2021 07:00 CET
Hørsholm, Denmark, August 09, 2021 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS... |
| 21.07.2021 | Update on a new clinical Phase Ib trial for the RH5.1 blood-stage malaria vaccine | Update on a new clinical Phase Ib trial for the RH5.1 blood-stage malaria vaccine Wed, Jul 21, 2021 08:30 CET
Hørsholm, Denmark, July 21, 2021 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") an... |
| 26.05.2021 | Announcement from ExpreS2ion's annual general meeting | Announcement from ExpreS2ion's annual general meeting Wed, May 26, 2021 10:39 CET
The annual general meeting 2021 ("AGM") of ExpreS2ion Biotech Holding AB ("ExpreS2ion" or the "Company") was held today on 26 Ma... |
| 19.05.2021 | ExpreS2ion Announces Financial Results for the First Quarter of 2021 | ExpreS2ion Announces Financial Results for the First Quarter of 2021 Wed, May 19, 2021 08:30 CET
Hørsholm, Denmark, May 19, 2021 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces its first quarter financial results for 2021. Th... |
| 31.03.2021 | ExpreS2ion’s platform (ExpreS2) featured in Viruses article on O-glycosylation on SARS-CoV-2 spike protein | ExpreS2ion’s platform (ExpreS2) featured in Viruses article on O-glycosylation on SARS-CoV-2 spike protein Wed, Mar 31, 2021 11:00 CET
ExpreS2ion Biotechnologies ApS (“ExpreS2ion”) and its protein production platform ExpreS2™ have contribut... |
